Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4096385 | 0.98 | — | — | |
| SCHEMBL16908465 | 0.77 | — | — | |
| SCHEMBL11676267 | 0.76 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15922502 | 0.74 | LMNA (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7462026 | 0.74 | KMT2A (0.33) | EPHX2MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28147128 | 0.74 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2056515 | 0.74 | — | — | |
| SCHEMBL23956811 | 0.73 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Phosphine SCHEMBL4096380 | 0.72 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL7452744 | 0.72 | KMT2A (0.33) | EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024235322-A1 | VERSATILE INTERMEDIATE FOR OPIOID DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 绍兴赜军生物医药科技有限公司 | 2024-11-21 | — | — | WO | claimed |
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12473384-B2 | Cyclopentadienyl/adamantyl phosphinimine titanium complexes | NOVA CHEMICALS (INTERNATIONAL) S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| EP-4139371-B1 | CYCLOPENTADIENYL/ADAMANTYL PHOSPHINIMINE TITANIUM COMPLEXES | NOVA CHEM INT SA (CH) | 2024-08-14 | — | — | EP | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20140121293-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| US-8546376-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2473495-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2012-07-11 | — | — | EP | disclosed |
| EP-2448941-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011033265-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | GRIN2D 1725/4885GRIN3B 1332/4885GRIN1 919/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | GRIN2D 2112/4885GRIN3B 2779/4885GRIN1 2149/4885 |
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GRIN2D 4051/4885GRIN3B 4323/4885GRIN1 2476/4885 |
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | GRIN2D 1644/4885GRIN3B 1111/4885GRIN1 424/4885 |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PLK1, MTOR | GRIN2D 4464/4885GRIN3B 2725/4885GRIN1 3409/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | GRIN2D 2112/4885GRIN3B 2779/4885GRIN1 2149/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | GRIN2D 1941/4885GRIN3B 1342/4885GRIN1 656/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | GRIN2D 1657/4885GRIN3B 1902/4885GRIN1 953/4885 |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CAMK2B, RYR2, CAMK2A | GRIN2D 963/4885GRIN3B 1001/4885GRIN1 541/4885 |
| US-12473384-B2 | Cyclopentadienyl/adamantyl phosphinimine titanium complexes | ACP1, CCT7, TCP1 | GRIN2D 3387/4885GRIN3B 3876/4885GRIN1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.